Table 3.

Cox proportional hazard regression models for the association between DPNP and mortality.

	Model 1				Model 2				Model 3
	HR	95%	CI	P	HR	95%	CI	P	HR	95%	CI	P
Screening by ID pain score
ID pain score < 2 (reference)	1.000				1.000				1.000
DPNP based on ID pain score ≥ 2	1.684	(1.324,	2.143)	<0.001	1.490	(1.167,	1.902)	0.001	1.394	(1.090,	1.782)	0.008
Screening by DN4 score
DN4 score < 4 (reference)	1.000				1.000				1.000
DPNP based on DN4 score ≥ 4	1.996	(1.457,	2.736)	<0.001	1.692	(1.230,	2.329)	0.001	1.668	(1.211,	2.297)	0.002
Screening by ID pain and DN4 scores
No neuropathic pain	1.000				1.000				1.000
DPNP by either the ID pain or DN4	1.511	(1.131,	2.020)	0.005	1.365	(1.018,	1.829)	0.038	1.273	(0.949,	1.709)	0.107
DPNP by both ID pain and DN4	2.122	(1.524,	2.954)	<0.001	1.787	(1.278,	2.498)	<0.001	1.713	(1.223,	2.398)	0.002

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, hypertension, CAD history, diabetes duration, HbA1c, HDL cholesterol, CKD, and UACR.

Model 3: adjusted for age, sex, hypertension, CAD history, diabetes duration, HbA1c, HDL cholesterol, CKD, UACR, and uses of antiplatelet drugs, antihypertensive drugs, insulin, and metformin.

CAD, coronary artery disease; CKD, chronic kidney disease; CI, confidence interval; DN4, Douleur Neuropathique en 4 questionnaire; DPNP, diabetic peripheral neuropathic pain; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HR, hazard ratio; ID pain, identification pain questionnaire; UACR, urine albumin-creatinine ratio.